Suppr超能文献

核磁共振光谱揭示大肠杆菌拓扑异构酶IV E亚基与抑制剂的结合模式

Escherichia coli Topoisomerase IV E Subunit and an Inhibitor Binding Mode Revealed by NMR Spectroscopy.

作者信息

Li Yan, Wong Ying Lei, Ng Fui Mee, Liu Boping, Wong Yun Xuan, Poh Zhi Ying, Liu Shuang, Then Siew Wen, Lee Michelle Yueqi, Ng Hui Qi, Huang Qiwei, Hung Alvin W, Cherian Joseph, Hill Jeffrey, Keller Thomas H, Kang CongBao

机构信息

From the Experimental Therapeutics Centre, Agency for Science, Technology, and Research (A*STAR), 31 Biopolis Way, Nanos, 03-01, Singapore 138669.

From the Experimental Therapeutics Centre, Agency for Science, Technology, and Research (A*STAR), 31 Biopolis Way, Nanos, 03-01, Singapore 138669

出版信息

J Biol Chem. 2016 Aug 19;291(34):17743-53. doi: 10.1074/jbc.M116.737429. Epub 2016 Jun 30.

Abstract

Bacterial topoisomerases are attractive antibacterial drug targets because of their importance in bacterial growth and low homology with other human topoisomerases. Structure-based drug design has been a proven approach of efficiently developing new antibiotics against these targets. Past studies have focused on developing lead compounds against the ATP binding pockets of both DNA gyrase and topoisomerase IV. A detailed understanding of the interactions between ligand and target in a solution state will provide valuable information for further developing drugs against topoisomerase IV targets. Here we describe a detailed characterization of a known potent inhibitor containing a 9H-pyrimido[4,5-b]indole scaffold against the N-terminal domain of the topoisomerase IV E subunit from Escherichia coli (eParE). Using a series of biophysical and biochemical experiments, it has been demonstrated that this inhibitor forms a tight complex with eParE. NMR studies revealed the exact protein residues responsible for inhibitor binding. Through comparative studies of two inhibitors of markedly varied potencies, it is hypothesized that gaining molecular interactions with residues in the α4 and residues close to the loop of β1-α2 and residues in the loop of β3-β4 might improve the inhibitor potency.

摘要

细菌拓扑异构酶是极具吸引力的抗菌药物靶点,因为它们在细菌生长中起着重要作用,且与其他人类拓扑异构酶的同源性较低。基于结构的药物设计是一种已被证实的有效开发针对这些靶点的新型抗生素的方法。过去的研究主要集中在开发针对DNA促旋酶和拓扑异构酶IV的ATP结合口袋的先导化合物。详细了解溶液状态下配体与靶点之间的相互作用将为进一步开发针对拓扑异构酶IV靶点的药物提供有价值的信息。在此,我们描述了一种已知的含有9H-嘧啶并[4,5-b]吲哚支架的强效抑制剂针对大肠杆菌拓扑异构酶IV E亚基(eParE)N端结构域的详细表征。通过一系列生物物理和生化实验,已证明该抑制剂与eParE形成紧密复合物。核磁共振研究揭示了负责抑制剂结合的确切蛋白质残基。通过对两种效力明显不同的抑制剂的比较研究,推测与α4中的残基、靠近β1-α2环的残基以及β3-β4环中的残基形成分子相互作用可能会提高抑制剂的效力。

相似文献

1
Escherichia coli Topoisomerase IV E Subunit and an Inhibitor Binding Mode Revealed by NMR Spectroscopy.
J Biol Chem. 2016 Aug 19;291(34):17743-53. doi: 10.1074/jbc.M116.737429. Epub 2016 Jun 30.
2
Backbone assignment of the N-terminal 24-kDa fragment of Escherichia coli topoisomerase IV ParE subunit.
Biomol NMR Assign. 2016 Apr;10(1):135-8. doi: 10.1007/s12104-015-9652-9. Epub 2015 Oct 19.
3
Characterization of the interaction between Escherichia coli topoisomerase IV E subunit and an ATP competitive inhibitor.
Biochem Biophys Res Commun. 2015 Nov 27;467(4):961-6. doi: 10.1016/j.bbrc.2015.10.036. Epub 2015 Oct 17.
5
Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
J Antimicrob Chemother. 2011 Sep;66(9):2061-9. doi: 10.1093/jac/dkr247. Epub 2011 Jun 21.
6
Biophysical Studies of Bacterial Topoisomerases Substantiate Their Binding Modes to an Inhibitor.
Biophys J. 2015 Nov 3;109(9):1969-77. doi: 10.1016/j.bpj.2015.10.001.
7
Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
J Med Chem. 2016 Oct 13;59(19):8941-8954. doi: 10.1021/acs.jmedchem.6b00864. Epub 2016 Sep 20.
8
Design and synthesis of peptides from bacterial ParE toxin as inhibitors of topoisomerases.
Eur J Med Chem. 2012 Aug;54:591-6. doi: 10.1016/j.ejmech.2012.06.008. Epub 2012 Jun 15.
10
New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
Eur J Med Chem. 2021 Mar 5;213:113200. doi: 10.1016/j.ejmech.2021.113200. Epub 2021 Jan 22.

引用本文的文献

1
Astaxanthin-Mediated Bacterial Lethality: Evidence from Oxidative Stress Contribution and Molecular Dynamics Simulation.
Oxid Med Cell Longev. 2021 Dec 9;2021:7159652. doi: 10.1155/2021/7159652. eCollection 2021.
2
A Practical Perspective on the Roles of Solution NMR Spectroscopy in Drug Discovery.
Molecules. 2020 Jun 28;25(13):2974. doi: 10.3390/molecules25132974.
3
Solution NMR Spectroscopy in Target-Based Drug Discovery.
Molecules. 2017 Aug 23;22(9):1399. doi: 10.3390/molecules22091399.

本文引用的文献

1
Application of Fragment-Based Drug Discovery against DNA Gyrase B.
Chempluschem. 2015 Aug;80(8):1250-1254. doi: 10.1002/cplu.201500197. Epub 2015 Jun 24.
2
Biophysical characterization of laforin-carbohydrate interaction.
Biochem J. 2016 Feb 1;473(3):335-45. doi: 10.1042/BJ20141555. Epub 2015 Nov 17.
3
Biophysical Studies of Bacterial Topoisomerases Substantiate Their Binding Modes to an Inhibitor.
Biophys J. 2015 Nov 3;109(9):1969-77. doi: 10.1016/j.bpj.2015.10.001.
4
Backbone assignment of the N-terminal 24-kDa fragment of Escherichia coli topoisomerase IV ParE subunit.
Biomol NMR Assign. 2016 Apr;10(1):135-8. doi: 10.1007/s12104-015-9652-9. Epub 2015 Oct 19.
5
Characterization of the interaction between Escherichia coli topoisomerase IV E subunit and an ATP competitive inhibitor.
Biochem Biophys Res Commun. 2015 Nov 27;467(4):961-6. doi: 10.1016/j.bbrc.2015.10.036. Epub 2015 Oct 17.
7
Structure of the N-terminal Gyrase B fragment in complex with ADP⋅Pi reveals rigid-body motion induced by ATP hydrolysis.
PLoS One. 2014 Sep 9;9(9):e107289. doi: 10.1371/journal.pone.0107289. eCollection 2014.
8
An alternate binding site for PPARγ ligands.
Nat Commun. 2014 Apr 7;5:3571. doi: 10.1038/ncomms4571.
9
Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
PLoS One. 2013 Dec 26;8(12):e84409. doi: 10.1371/journal.pone.0084409. eCollection 2013.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验